Amgen | AMGN - Operating Expenses


Amgen reported $11.69B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 359.47M 3.28M Mar/2026
Genmab DKK 798M 235M Dec/2025
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 17.83B 388M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Moderna USD 960M 817M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Takeda JPY 1.02T 89.68B Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026